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A protein inhibitor (CMTI-V; && 7106) of trypsin and activated Hageman factor (Factor XII,), a serine protease involved in blood coagulation, 
has been isolated for the first time from pumpkin (Cuca&~n maxima) seeds by means of trypsin-afhnity chromatography and reverse phase high 
performance liquid chromatography (HPLC). The dissociation constants of the inhibitor complexes with trypsin and Factor XII. have been deter- 
mined to be 1.6 x 10-a and 4.1 x 1Om8 M, respectively. The primary structure of CMTI-V is reported. The protein has 68 amino acid residues and 
one disulfide bridge and shows a high level of sequence homology to the Potato I inhibitor family. Furthermore, its amino terminus consists of 
an N-acetylates Ser. The reactive site has been established to be the peptide bond between LY$~-As~~~. The moditied inhibitor which has the reactive 
site peptide bond hydrolyzed inhibits trypsin but not the Hageman factor. 
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1. INTRODUCTION 
Protein inhibitors of trypsin and activated Hageman 
factor were isolated from pumpkin (Cucurbita maxima) 
seeds by Polanowski et al. [l] and Hojima et al. [2,3], 
independently. Elaborate work by the former group led 
to the isolation of 3 iso-inhibitors (& -3OOO), termed 
CMTI-I, CMTI-III, and CMTI-IV, and the determina- 
tion of their amino acid sequences [4]. These protein in- 
hibitors each have 3 disulfide bridges and are believed 
to be the smallest known globular trypsin i~ibitors. 
Recently, an X-ray c~st~lographic structure of the 
CMTI-I-trypsin complex was reported by Bode et at. 
151. The inhibitor binds to the enzyme in the same way 
as does a substrate. Our interest in characterizing the 
solution structures of these proteins by nuclear 
magnetic resonance (NMR) spectroscopy prompted us 
to develop a rapid resolution-enhanced method of isola- 
tion. As a result, using trypsin-affinity chromatography 
followed by reversed phase high perfomance liquid 
chromatography (HPLC), we have now isolated for the 
first time a higher molecular mass protein (&& - 7106; 
CMTI-V) which specifically inhibits both trypsin and 
activated Hageman factor, but not plasma kallikrein, 
another serine protease closely related to Hageman fac- 
tor. We report here the isolation, inhibitory properties, 
and primary structure of CMTI-V. 
2. MATERIALS AND METHODS 
Pumpkin seeds (commercially known as Big Max, Cucurbita max- 
ima) were purchased from Northrup King Co. Trypsin-affinity COI- 
umn chromato~aphy matrix was purchased from Bio-Rad. Enzymes 
used were obtained as indicated: bovine trypsin (Sigma), activated 
Hageman factor (~lbi~hem), and plasma kallikrein (Helena 
Laboratories). The two trypsin substrates used in the determination 
of dissociation constants of the enzyme-inhibitor complexes were 
benzoyl-L-Arg-p-nitroanilide (BAPNA; Sigma) and D-Pro-Phe-Arg- 
p-nitroanilide (S-2302; Helena Laboratories). All other reagents and 
supplies were reagent grade or better. 
2.1. Isolation of Protein Inhibitors 
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The seeds were defatted and the crude proteins were precipitated by 
salting out with ammonium sulfate. The sediment was dissolved in 
water, dialyzed, and centrifuged. The clear supematant liquid was 
subjected to trypsin-affinity chromatography using an Affi-Prep10 
column to which trypsin had been attached. The trypsin inhibitors 
were liberated by using a glycme buffer @H 2.0), as described by Lei 
and Reeck 161. The fractions were subjected to reverse phase HPLC 
after dialysis and lyophilization using a Varian system Model 2510 
and a Varian C-18 Protein Column: the two solvents employed were 
0.1% (v/v) trifluoroacetic acid (TFA) in water (Solvent A) and 0.1% 
(v/v) TFA in acetonitrile (Solvent B). During elution (flow rate 2.0 
ml/min) a gradient was employed such that in 60 min the solvent com- 
position altered from 0% to 40% (v/v) B. It was further changed to 
100% B in 15 min and finally changed back to 0% B in 15 min. The 
eluent was monitored with an ISCO detector at 280 nm. Fractions 
labeled a, b, c, d, e, and f were collected and re-chromatographed to
homogeneity. 
Published by Elsevier science Pub/i&em B. V. ~Biom~icaI Wvision] 
~145793/~/$3.50 0 1990 Federation of European Biochemical Societies 163 
Volume 273, number 1,2 FEBS LETTERS October 1990 
2.2. Enqme rnhibit~o~ Assays 
Inhibition of trypsin was followed by monitoring the rate of 
hydrolysis of BAPNA spectrophotometrically at 405 nm ]7]. Similar- 
ly, inhibition of activated Hageman factor and of plasma kallikrein 
was determined by following the hydrolysis of S-2302. The dissocia- 
tion constants (Ki) of the enzyme-inhibitor complexes were determin- 
ed by the method of Bieth [8]. Stoichiometric oncentrations in the 
lo-’ M range of the inhibitors and the enzymes were used. the 
substrate concentration was of the order of 10m4 M. 
2.3. Polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel dectrophoresis (SDS- 
PAGE) was performed using 18% polyacrylamide and 0.4% N,N- 
methyiene-bis acrylamide as described by Laemmli [9]. Protein bands 
were visualized by staining with a Coomassie brilliant blue solution. 
Protein standards (Low range kit; Diversified Biotech) for molecular 
mass in the range 2-21 kDa were used. 
2.4. Amino acid analysis 
The method described by Bidlingmeyer et al. [lo] was used. The in- 
hibitors were hydrolyzed in 6 M hydrochloric acid for 24 h at 105°C 
and the liberated amino acids were reacted with phenylisothiocyanate 
(Pierce Chem. Co.) to form the phenylthiocarbamate d rivatives with 
were then analyzed by reverse phase HPLC on a Pica-Tag column 
(Waters Associates). Cysteines were determined by the method of 
Moore [ill. 
2.5. Amino acid sequencing 
An applied Biosystems Model 47719 Sequencer/M~el 120A PTH 
Analyzer system was employed for the automatic determination of 
amino acid sequences of the inhibitor molecules using the Edman 
degradation. The phenylthiohydantoin derivatives were identified by 
reverse phase HPLC. Cysteines were derivatized by in situ alkylation 
using 4-vinylpyridine as shown by Andrews and Dixon [12]. CMTI-e 
and CMTI-f were reduced and S-carboxymethylated asdescribed in 
[ 131. The components present in CMTI-f were subsequently separated 
by gel filtration on a column (1 x 200 cm) of Biogel P6 in 0.1 M am- 
monium bicarbonate pH 8.1. Samples of the reduced and carboxy- 
methylated proteins were digested separately with chymotrypsin, pep- 
sin and the protease from S. uureus V8 as in [14]. A further sample 
of CMTI-e was treated with cyanogen bromide (lOO-fold molar ex- 
cess) in 70% formic acid for 24 h at 20°C. The peptides resulting from 
these treatments were purified by reverse phase HPLC on a Varian 
5000 HPLC fitted with a Vydac Cl8 cofumn (25 cm x 4.6 mm; 
218TPS4, Technical, Stockport) using variable gradients of O-70% 
acetonitrile (HPLC grade, S. Rathbum) in 0.1% trifluoroacetic acid 
as described in [14]. The peptides obtained were sequenced using the 
manual 4-N,N-dimethylaminoazobenzene-4’-isothiocyanate 
(DABITC)/phenylisothiocyanate (PITC) double coupling method 
1151. 
Attempts were made to unblock the N-terminus of CMTI-e by 
treatment with pyroglutamate aminopeptidase as described in [16], 
methanolysis with cont. HCl/methanol (1:ll v/v) for 48 h at 20°C as 
in [17] and by anhydrons TFA as described in [18]. 
3. RESULTS AND DISCUSSION 
A typical reverse phase HPLC result obtained after 
trypsin-affinity chromatography is displayed in Fig. 
1A: six peaks, identified a-f, are noted. They are term- 
ed CMTI-a through CMTI-f, respectively, following 
the terminology of Wieczorek et al. [4]. Figs IB and 1C 
depict the inhibitory activity towards trypsin and ac- 
tivated Hageman factor, respectively, of each of the 
eluent fractions collected during the course of time. 
None of the fractions obtained inhibited plasma 
kallikrein. Trypsin can cleave the reactive site peptide 
164 
bond of a virgin in~bitor in the e~me-i~ibitor com- 
plex, thus producing its modified form [19]. In order to 
identify peaks that are produced this way, each of the 
proteins, CMTI-a, CMTI-b, CMTI-c, and CMTI-e, 
was reacted with trypsin and the reaction mixture was 
analyzed by reverse phase HPLC. The results (not 
shown) reveal that CTMI-a and CMTI-c form one pair 
of virgin and modified inhibitors, CMTI-b and CMTI-d 
form a second pair, and, CMTI-e and CMTI-f make the 
third pair. 
Polyacril~ide gel electrophoresis of these inhibitors 
indicated that CMTI-a through CMTI-d each had a 
molecule mass of about 3 kDa, whereas CMTI-e and 
CMTI-f each had a molecular mass of about 7 kDa. 
In order to identify the virgin and modified inhibitor 
in each pair, we resorted to amino acid sequencing. The 
automated sequencing of amino acid residues for 
CMTI-a revealed the presence of two amino termini; 
one had the sequence, RVCPR, and the other, ILMKC, 
thus unambiguously identifying it as the modified 
form. Furthermore, the complete sequencing of CMTI- 
c, the other protein in the pair, established with certain- 
ty that it was indeed the same protein as the one termed 
CMTI-III, by Wieczorek et al. 141. Simil~ly complete 
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Fig. 1. Isolation and inhibitory activities of pumpkin seed inhibitors. 
(A) Reverse phase HPLC; see text for elution details. (B) Inhibition 
of trypsin; (C) Inhibition of activated Hageman factor. Inhibition of 
the enzyme by each fraction (0.5 ml) is expressed as percentage of 
maximum inhibition observed. 
Volume 273, number I,2 FEBS LETTERS October 1990 
amino acid sequencing of CMTI-b proved that it had 
two amino termini and the complete sequence matched 
that of the protein, identified as CMTI-I by the same 
workers [4]. Because CMTI-d was produced from 
CMTI-b by reaction with trypsin, we conclude that 
CMTI-d is the virgin form of CMTI-b. 
Determination of the amino acid composition of 
CMTI-e (CMTI-V; data not shown) proved that CMTI- 
e was certainly not a dimer of any of the 3 kDa proteins. 
It was also found that CMTI-e had only disulfide 
Iinkage, which is unusual, and that it had a high proline 
content of 8.3 residues. Initial attempts to sequence 
CMTI-e by automated means revealed that it had a 
blocked N-terminus. However, similar efforts with 
CMTI-f yielded the sequence: DFRCNRVRIWVN- 
KRGLVVSTPRI, which was later shown to be the first 
23 residues of the C-terminal fragment which resulted 
from trypsin-catalyzed cleavage of the reactive site pep- 
tide bond (PI ’ ; [ 191) which occurred during the affinity 
step of purification. The modified nature of CMTI-f 
was confirmed when it was shown that after reduction 
and S-carbox~ethylation the protein could be 
separated into 3 fragments by gel filtration on Biogel P6 
or by reverse phase HPLC. The largest fragment (68 
residues) was the intact protein, and the two other 
fragments (44) and 24 residues) were respectively the N- 
and C-terminal fragments resulting, from the cleavage 
of the reactive site. 
CMTI-f could be converted back to CMTI-e by reac- 
tion with trypsin followed by HPLC analysis. Thus it is 
established that CMTI-e is the virgin inhibitor, whereas 
CMTI-f is the modified form in which the reactive site 
peptide bond is hydrolyzed. Following the convention 
of Wieczorek et al. [4], we term the new protein in- 
hibitor CMTI-e as CMTI-V. 
10 
Attempts to unblock the N-terminus of the intact 
CMTI-V by digestion with pyroglutamate aminopep- 
tidase were unsuccessful. However, treatments of the 
inhibitor with cont. HCl/methanol [17] or with 
anhydrous TFA [18] subsequently permitted the N- 
terminal sequence of SSCPGKSS to be determined in- 
dicating that the terminal serine was probably N- 
acetylated, The 400 MHz NMR spectrum of CMTI-V 
shows a sharp uncoupled peak at -2.1 ppm (not 
shown) which could be attributed to the CH3 of the 
acetyl group. The complete amino acid sequence of in- 
hibitor CMTI-V is shown in Fig. 2 together with the 
overlapping peptides from which it was deduced. 
The structure of CMTI-V shows clear and strong se- 
quence similarities with the potato I iso-inhibitors 
[20-221, inhibitors from tomato leaves [23], barley [24], 
bean 1251 and also with the leech inhibitor eglin [26]. It 
should be noted that other workers have previously 
reported a trypsin inhibitor from seeds of Momordica 
chmzntia (Cucurbitaceae) which also had a weak 
homology with the members of the potato I family 1271. 
Our finding that CMTI-f is a modified form of CMTI- 
V and the determination of the amino acid sequences of 
both proteins show that the peptide bond Ly~?-Asp~~ 
is the trypsin reactive (inhibitory) site of the pumpkin 
inhibitor. When the sequences of the potato I family of 
inhibitors are aligned (Fig. 3) this bond in the pumpkin 
CMTI-V protein occurs in exactly the same position as 
the reactive sites in all of the other inhibitors. 
In Table I are collected the dissociation constants of 
the complexes formed between the various inhibitors 
and the enzymes, trypsin and activated Hageman fac- 
tor. The inhibitor activity towards activated Hageman 
factor is Iost in each of the two modified 3kDa proteins 
(CMTI-a and CMTI-b) and the modified form of the 
20 30 
40 1 50 60 
I-L-E-E-G-T-P-V-T-K-D-F-R-C-N-R-V-R-I-W-V-N-K-R~-L-V-V-S-P-P-R-I-G 
_____-_____________r~~~~~~~~~~~~~_~_~~~~~~~~~~~ 
_______)<____V5______ )<_V6__)<--V,-___>(_--____VS_______-- 
<--__V~a-_______> <__-a-V&m_----> 
-__)<_______C4________-> 
-_-C3a____________-____> 
<_~-~~~~~~___CN~~----~~~~-__> 
<___p4- <___--_p5--_ 
Fig. 2. The amino acid sequence of trypsin inhibitor CMTI-V (CMTI-e) from seeds of pumpkin (t%curbifu muximu). V, peptides from digestion 
with S. uureus VS protease; C, chymotryptic peptides; P, peptic peptides; CN, fragments from cleavage with cyanogen bromide; MH, sequence 
determined after treatment of CMTI-V with cont. HCllmethanol or anhydrous TFA. (-+) indicates residues determined by automated egradation 
in pulsed phase sequencer; all other residues determined by DABITClPITC method. (1) indicates reactive site peptide bond cleaved by trypsin on 
affinity column which converts CMTI-V to modified form CMTI-f. 
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KrMTo 1 FAMILY 
1 10 
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(T.R,R,G,v)R f, D P 
TEFGSELK-SFPEVVGK 
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GGSYA-- KAIfER9NPNVRAY_ILE&GTP 
PTKLA-- KETIBKQNSLXTNVHXLLNGSP 
G S Q K 
PTKLA--KEIIGKENPSITN~PILLSGSP 
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TVDQA --REYFT- LHYPQYNVYPLPEGSP 
1 50 60 
VTKDPRCN-RVRTWVNKRGLVVS-PPRIG 
VTMDYRCN-RYRLPDNILGNVVE-IPRvG 
t p D S D L VLA 
L Y 
ITLDYLCD-RVRLPDNILGPVVQ-BPVVT 
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Fig. 3, Alignments of the amino acid sequences of the members of the potato I family of proteinase inhibitors. (1) CMTI-V inhibitor of trypsin 
and activated Hageman factor from pumpkin (Cucurbila maxima) seeds; (2) iso-inhibitors of chymotrypsin from tubers of potato [20-221; (3) 
inhibitor I from wounded leaves of tomato [23]; (4) chymotrypsin inhibitor 2 from seeds of barley [24]; (5) subtilisin inhibitor from seeds of broad 
bean (Viciafaba) [25]; (6) trypsin inhibitor from seeds of Momordicu charuntia [273; (7) inhibitor eglin from leech (Hiruda medicinualis) [26]. (1) 
indicates position of reactive site peptide bond (not determined in Momordica and leech proteins). 
newly isolated 7 kDa protein (CMTE-0. On the other 
hand, trypsin inhibition is demonstrated by all of them. 
CMTIa (which is the same as CMTI-III [4]) and CMTI- 
d (which is the same as CMTI-I [4]) differ from each 
other by a single amino acid substitution: Lys-9 in 
CMTI-III has been replaced by a Glu in CMTI-I ([4] 
and present work). However, this subsitution at P’4 
Table I 
Comparison of dissociation constants (J&J for the complex of 
pumpkin seed trypsin inhibitors (CMTI), barley trypsin inhibitor 
(BTI), and corn Hageman factor inhibitor (CHFI) with trypsin and 
activated Hageman factor. 
Protein Trypsin 
Ir'i WI 
Hageman factor Ref. 
G WI 
CMTI-a 
CMTI-b 
CMTI-c 
CMTI-d 
CMTI-Y 
BTI 
CHFI 
CMlY 
2.2x 10-s n.d, 
5.1 x 10-9 n.d. 
2.4x lo-’ 2*9x 10-s 
1.7x 10-s 2.2x 10-s 
1.6x lo-’ 4.1x10-s 
2.3 x lo-’ 
2.2X 10-s 
I.3xio-8 
1.1 x lO-7 
2.1 x10-9 
4.1x 10-s 
This work 
This work 
This work 
This work 
This work 
171 
[71 
131 
nd. not determined because of absence of stoichiometric binding 
(loose binding). a Eased on amino acid composition, Hojima et al. p] 
suggest his to be the same as CMTI-III of Wieczonzk et al. [4]. 
position has no effect on the stability of the enzyme-in- 
hibitor complexes formed with trypsin and activated 
Hageman factor gable I). Furthermore, in spite of 
their very different primary structures both the 3 kDa 
proteins (CMTE-I and CMTI-XII) and the presently 
discovered 7 kDa protein (CMTI-V form complexes of 
similar stability with trypsin and with activated 
Hageman factor. The results thus indicate not only the 
stringent structural requirement of an inhibitor to 
specifically inhibit activated Hageman factor, but also 
the preservation of similar structural features in the ap- 
parently unrelated 3 kDa and 7 kDa trypsin inhibitors 
from pumpkin seeds. Interestingly, the association 
equilibria constants determine by Wyn and 
Laskowski for CMTI-I and CMTI-III with the 
Hageman factor reveal that the value for CMTI-III is 
about 62 times that for CMTI-I f28]. We are currently 
carrying out NMR studies of CMTI-V to determine its 
three-dimensional solution structure. 
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